Comparing PCSK9 Inhibitor Regimens for Patients with Established Atherosclerotic Cardiovascular Disease: A Network Meta-analysis

Table of Contents

• Key Points
• Background: Why This Research Matters
• How the Research Was Conducted
• Overview of Included Trials and Patient Characteristics
• Key Finding: Major Adverse Cardiovascular Events
• Key Finding: Heart Attack, Stroke, Revascularization, and Death
• How This Study Compares with Previous Meta-analyses
• How PCSK9 Inhibitors Work: Beyond LDL Cholesterol Lowering
• Clinical Implications: What This Means for Patients
• Limitations: What the Study Could Not Prove
• Recommendations and Takeaways
• Frequently Asked Questions
• Source Information

Key Points

• In a network meta-analysis of 49,847 patients with established atherosclerotic cardiovascular disease, evolocumab and alirocumab 150 mg every 2 weeks significantly reduced major adverse cardiovascular events versus placebo.
• No PCSK9 inhibitor regimen in this analysis significantly reduced cardiovascular death or all-cause death compared with placebo.
• Evolocumab reduced heart attack, stroke, and revascularization; alirocumab 75 mg reduced stroke; alirocumab 150 mg reduced stroke and revascularization.
• The authors state that regimens achieving deeper and more sustained LDL cholesterol lowering may confer greater benefit, consistent with the concept that lower is better.
• These findings are hypothesis-generating and need confirmation in adequately powered, direct head-to-head trials before guiding clinical decision-making.

Background: Why This Research Matters

Atherosclerotic cardiovascular disease (ASCVD) remains the leading cause of illness and death worldwide. This is true even though high-intensity statins and other evidence-based therapies are widely used. In patients with established ASCVD, a substantial residual risk of cardiovascular events persists even after aggressive lipid (cholesterol) lowering. This residual risk highlights the need for additional treatment strategies.

This high-risk population typically has atherosclerotic plaques (fatty deposits in artery walls) that show features of instability. Unstable plaques carry an elevated risk of adverse cardiovascular events.

In this context, targeting a protein called proprotein convertase subtilisin/kexin type 9 (PCSK9) has emerged as a biologically compelling and clinically impactful approach. PCSK9 inhibitors (PCSK9i) include monoclonal antibodies such as evolocumab and alirocumab, as well as small-interfering RNA agents such as inclisiran. These drugs have reshaped lipid management by enabling profound and sustained reductions in low-density lipoprotein cholesterol (LDL-C) levels.

Multiple placebo-controlled trials conducted in patients with ASCVD have demonstrated the clinical efficacy of PCSK9 inhibitors in reducing cardiovascular events. However, differences in molecular mechanisms, pharmacokinetics (how the body processes a drug), dosing intervals, and trial populations have raised questions. These differences have raised questions about whether there is a "class effect" of these agents in reducing cardiovascular events.

In the absence of head-to-head comparisons, treatment selection is often guided by practical considerations. These include adherence, dosing frequency, and tolerability, rather than expectations of differential efficacy. To address this gap, the researchers conducted a comprehensive network meta-analysis of randomized controlled trials. A network meta-analysis is a statistical method that allows comparison of multiple treatments across different studies, even when those treatments were not directly compared in a single trial.

How the Research Was Conducted

The researchers included randomized controlled trials (RCTs) enrolling adult patients with established ASCVD. Patients were treated with a PCSK9 inhibitor (evolocumab, alirocumab, or inclisiran) at an approved dosage. Eligible trials were required to report at least one clinical cardiovascular outcome. These outcomes included major adverse cardiovascular events (MACE), myocardial infarction (heart attack), stroke, coronary revascularization (procedures to restore blood flow to the heart), cardiovascular death, or all-cause death.

Trials enrolling primary prevention patients without evidence of ASCVD were excluded. So were individuals with ASCVD risk equivalents, such as familial hypercholesterolemia without prior events. The researchers also excluded nonrandomized studies, observational designs, and studies lacking outcome data. In all included trials, the comparator arms consisted of either placebo added to background statin therapy or standard statin therapy alone.

The literature searches and all analyses followed the Cochrane collaboration and Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) statements. The study protocol was registered in PROSPERO (ID: CRD420251022108).

Definition of clinical outcomes: The primary endpoint was MACE, analyzed on a time-to-first-event basis. When MACE and its definition were explicitly reported in the original trial, the researchers adopted the trial-defined composite. When MACE was not reported as a composite, they derived it by aggregating the individual endpoints conventionally part of three- or four-point MACE. These individual endpoints were cardiovascular death, myocardial infarction, stroke, and coronary revascularization, as available from each study.

The secondary endpoints included all-cause mortality and the individual components of the MACE composite. These components were myocardial infarction, stroke, cardiovascular death, and revascularization.

Data extraction and quality assessment: Two investigators independently screened titles and abstracts of all records retrieved through the search strategy. They used Rayyan, a web-based platform developed to assist in the systematic review screening process. The same two authors independently extracted data from eligible studies. A third investigator verified the consistency of data extraction and decided upon controversies. The final list of included studies was decided upon discussion between authors, with full agreement required prior to inclusion.

Risk-of-bias assessment was conducted by two authors in duplicate. They used version 2 of the Cochrane risk-of-bias tool for RCTs (RoB 2). This tool evaluates five domains of bias for each outcome. The five domains are the randomization process, deviations from intended interventions, missing outcome data, the measurement of the outcome, and the selection of the reported results.

Statistical analysis: A Bayesian hierarchical network meta-analysis was performed using the BUGSnet package on R. Fixed- and random-effect models were selected for each outcome on the basis of the smallest deviance information criteria. Analyses were performed using Markov-chain Monte Carlo methods, based on 100,000 iterations with a burn-in of 10,000. Convergence was assessed with the Gelman–Rubin convergence diagnostic test. A frequentist random-effect network meta-analysis was also performed using the packages netmeta and dmetar on R.

All outcomes were analyzed as risk ratios (RRs) with corresponding 95% confidence intervals (CIs). Two-tailed P-values of 0.05 were used for statistical significance. The P-score statistic was used to assess the mean probability of superiority of each strategy to alternative treatments for a given outcome. Statistical heterogeneity was tested using the I² values.

Overview of Included Trials and Patient Characteristics

The search identified eight eligible randomized controlled trials and included a total of 49,847 patients. Among the included trials, four evaluated evolocumab (n = 14,504 patients). Three assessed alirocumab, including 9,492 patients treated with 75 mg every 2 weeks (Q2W) and 148 patients treated with 150 mg Q2W. One trial investigated inclisiran (n = 781 patients).

The mean follow-up ranged from 3 months to nearly 3 years. The eight trials were ODYSSEY OUTCOMES (2018), FOURIER (2017), ORION 10 (2020), HUYGENS (2022), PACMAN-AMI (2022), Gao et al. (2021), GLAGOV (2016), and EVOPACS (2019).

Key characteristics of the included trials:

• ODYSSEY OUTCOMES (2018): 18,924 patients, double-blinded, 1,022 days of clinical follow-up. Treatment was alirocumab 75 mg Q2W. Mean age was 58.5 years in the treatment group and 58.6 years in the control group. Men made up 74.7% of the treatment group and 74.9% of the control group. Hypertension was present in 65.6% of the treatment group and 63.9% of the control group. Diabetes was present in 28.5% of the treatment group and 29.1% of the control group. Mean BMI was 28.5 kg/m² in both groups. Previous heart attack was reported in 18.9% of the treatment group and 19.5% of the control group. Previous PCI (percutaneous coronary intervention) was reported in 17.2% of the treatment group and 17.1% of the control group. Previous CABG (coronary artery bypass graft) was reported in 5.5% of the treatment group and 5.6% of the control group. Baseline LDL-C was 92 mg/dL in both groups.
• FOURIER (2017): 27,564 patients, double-blinded, 336 days of clinical follow-up. Treatment was evolocumab 140 mg Q2W or 420 mg monthly (QM). Mean age was 62.5 years in both groups. Men made up 75.4% of the treatment group and 75.5% of the control group. Hypertension was present in 80.1% of both groups. Diabetes was present in 36.7% of the treatment group and 36.5% of the control group. Previous heart attack was reported in 80.9% of the treatment group and 81.3% of the control group. Baseline LDL-C was 92 mg/dL in both groups.
• ORION 10 (2020): 1,561 patients, double-blinded, 510 days of clinical follow-up. Treatment was inclisiran 284 mg. Mean age was 66.4 years in the treatment group and 65.7 years in the control group. Men made up 68.5% of the treatment group and 70.3% of the control group. Hypertension was present in 91.4% of the treatment group and 89.9% of the control group. Diabetes was present in 47.5% of the treatment group and 42.4% of the control group. Baseline LDL-C was 104.5 mg/dL in the treatment group and 104.8 mg/dL in the control group.
• HUYGENS (2022): 161 patients, double-blinded, 350 days of clinical follow-up. Treatment was evolocumab 420 mg QM. Mean age was 60.9 years in the treatment group and 60.2 years in the control group. Men made up 75% of the treatment group and 67.9% of the control group. Hypertension was present in 56.3% of the treatment group and 40.7% of the control group. Diabetes was present in 16.3% of the treatment group and 17.3% of the control group. Mean BMI was 28.2 kg/m² in the treatment group and 28 kg/m² in the control group. Previous heart attack was reported in 6.3% of the treatment group and 11.1% of the control group. Previous PCI was reported in 11.3% of the treatment group and 14.8% of the control group. Baseline LDL-C was 140.4 mg/dL in the treatment group and 142.1 mg/dL in the control group.
• PACMAN-AMI (2022): 300 patients, double-blinded, 364 days of clinical follow-up. Treatment was alirocumab 150 mg Q2W. Mean age was 58.4 years in the treatment group and 58.6 years in the control group. Men made up 83.8% of the treatment group and 78.3% of the control group. Hypertension was present in 40.5% of the treatment group and 46.1% of the control group. Diabetes was present in 8.1% of the treatment group and 12.5% of the control group. Mean BMI was 27.3 kg/m² in the treatment group and 28.2 kg/m² in the control group. Previous heart attack was reported in 1.4% of the treatment group and 3.3% of the control group. Previous PCI was reported in 1.4% of the treatment group and 3.3% of the control group. Baseline LDL-C was 154.8 mg/dL in the treatment group and 150.9 mg/dL in the control group.
• Gao et al. (2021): 61 patients, not blinded, 252 days of clinical follow-up. Treatment was alirocumab 75 mg Q2W. Mean age was 66.7 years in the treatment group and 74.2 years in the control group. Men made up 20% of the treatment group and 23% of the control group. Hypertension was present in 17% of the treatment group and 19% of the control group. Diabetes was present in 7% of the treatment group and 8% of the control group. Previous heart attack was reported in 4% of the treatment group and 3% of the control group. Baseline LDL-C was 118 mg/dL in the treatment group and 123 mg/dL in the control group.
• GLAGOV (2016): 968 patients, double-blinded, 532 days of clinical follow-up. Treatment was evolocumab 420 mg QM. Mean age was 59.8 years in both groups. Men made up 72.1% of the treatment group and 72.3% of the control group. Hypertension was present in 82.2% of the treatment group and 83.7% of the control group. Diabetes was present in 20.2% of the treatment group and 21.5% of the control group. Mean BMI was 29.4 kg/m² in the treatment group and 29.5 kg/m² in the control group. Previous heart attack was reported in 34.9% of the treatment group and 35.3% of the control group. Previous PCI was reported in 39% of the treatment group and 38.8% of the control group. Baseline LDL-C was 92.6 mg/dL in the treatment group and 92.4 mg/dL in the control group.
• EVOPACS (2019): 308 patients, double-blinded, 56 days of clinical follow-up. Treatment was evolocumab 420 mg QM. Mean age was 60.5 years in the treatment group and 61 years in the control group. Men made up 83% of the treatment group and 80% of the control group. Hypertension was present in 51% of the treatment group and 56% of the control group. Diabetes was present in 15% of the treatment group and 16% of the control group. Mean BMI was 26.9 kg/m² in the treatment group and 27.8 kg/m² in the control group. Previous heart attack was reported in 15% of the treatment group and 12% of the control group. Previous PCI was reported in 16% of the treatment group and 15% of the control group. Previous CABG was reported in 3% of both groups. Baseline LDL-C was 146 mg/dL in the treatment group and 148 mg/dL in the control group.

Key Finding: Major Adverse Cardiovascular Events

Among the included PCSK9 inhibitor regimens, two demonstrated a statistically significant reduction in MACE compared with placebo. Evolocumab 420 mg monthly (QM) or 140 mg every 2 weeks (Q2W) showed a significant effect on the composite outcome, with a risk ratio (RR) of 0.78 and a 95% confidence interval (CI) of 0.66–0.93. This means patients taking evolocumab had a 22% lower risk of major cardiovascular events compared with placebo.

Alirocumab 150 mg Q2W was also associated with a significant reduction in MACE, with an RR of 0.47 and a 95% CI of 0.25–0.86. This means patients taking alirocumab 150 mg Q2W had a 53% lower risk of major cardiovascular events compared with placebo.

Other regimens did not show statistically significant reductions in MACE compared with placebo.

In comparisons between agents, a statistically significant difference was observed between alirocumab 150 mg and inclisiran. This difference favored alirocumab in terms of MACE reduction, with an RR of 0.37 and a 95% CI of 0.16–0.83. No other indirect comparisons among PCSK9 inhibitors showed statistically significant differences for the primary endpoint.

Key Finding: Heart Attack, Stroke, Revascularization, and Death

Secondary outcomes included all-cause mortality and the individual components of the MACE composite: myocardial infarction (heart attack), stroke, cardiovascular death, and coronary revascularization.

Among these, evolocumab 420 mg QM/140 mg Q2W was associated with a statistically significant reduction in several outcomes compared with placebo:

• Myocardial infarction (heart attack): RR 0.72, 95% CI 0.56–0.90 (28% lower risk)
• Revascularization: RR 0.77, 95% CI 0.67–0.88 (23% lower risk)
• Stroke: RR 0.76, 95% CI 0.60–0.94 (24% lower risk)

Alirocumab 75 mg Q2W significantly reduced the incidence of stroke, with an RR of 0.71 and a 95% CI of 0.54–0.94 (29% lower risk).

Alirocumab 150 mg Q2W demonstrated statistically significant effects on both stroke and revascularization:

• Stroke: RR 0.13, 95% CI 0.01–0.93 (87% lower risk)
• Revascularization: RR 0.39, 95% CI 0.20–0.74 (61% lower risk)

Notably, for revascularization, comparisons between agents showed that alirocumab 150 mg Q2W was associated with a statistically significant reduction in events. This reduction was compared both with alirocumab 75 mg Q2W (RR 0.45, 95% CI 0.22–0.87) and with evolocumab 420 mg QM/140 mg Q2W (RR 0.51, 95% CI 0.25–0.97).

None of the evaluated PCSK9 inhibitor regimens were associated with a significant reduction in cardiovascular death or all-cause mortality compared with placebo.

How This Study Compares with Previous Meta-analyses

According to the authors, this is the first network meta-analysis to compare individual PCSK9 inhibitor regimens and dosages in patients with established ASCVD, focusing on clinical cardiovascular outcomes.

Two recent network meta-analyses have explored the role of PCSK9 inhibitors in cardiovascular prevention, though with markedly different aims and methodological frameworks compared with this study.

Toth et al. focused primarily on LDL-C lowering, comparing PCSK9 inhibitors with other lipid-lowering agents such as ezetimibe and bempedoic acid. While valuable from a mechanistic standpoint, that analysis did not assess clinical cardiovascular outcomes, nor did it focus on a specific risk population.

Wang et al., by contrast, addressed clinical endpoints including all-cause mortality and myocardial infarction. However, that analysis included a mixed population of patients with ASCVD and ASCVD risk equivalents, introducing heterogeneity (variation) in the selection of the baseline population. Moreover, that analysis pooled different dosing regimens of the same agents and did not stratify results by individual PCSK9 inhibitor dosage or schedule.

This study differs in key aspects. First, the researchers included only patients with established ASCVD, ensuring a clinically more homogeneous population. In this population, the pathophysiological substrate of plaque instability, inflammation, and thrombosis renders patients more responsive to intensive lipid-lowering strategies. Furthermore, the researchers evaluated the individual PCSK9 inhibitor regimens and dosages separately. The exception was evolocumab 140 mg Q2W and 420 mg QM, which were analyzed together owing to their established clinical equivalence. This approach provides a more nuanced understanding of the potential differential effects of each regimen, including inclisiran, despite the currently limited evidence available for this agent.

How PCSK9 Inhibitors Work: Beyond LDL Cholesterol Lowering

PCSK9 is a hepatic protease (a liver enzyme) that plays a key role in lipid metabolism. It promotes the degradation of LDL-C receptors on the surface of hepatocytes (liver cells). By binding to LDL-C receptors, PCSK9 targets them for lysosomal degradation, thereby reducing their availability to clear circulating LDL-C cholesterol.

PCSK9 inhibitors are monoclonal antibodies or small interfering RNA that block this interaction or silence the translation of PCSK9 messenger RNA, respectively. This enhances the recycling of LDL-C receptors to the cell surface. Ultimately, this increases hepatic clearance of LDL-C particles from the bloodstream. This mechanism results in a profound and sustained reduction in plasma LDL-C levels, which is the primary driver of their cardiovascular benefit.

However, evidence suggests that the benefits of PCSK9 inhibitors extend well beyond mere lipid modulation, particularly in patients with established ASCVD. In this population, atherosclerotic plaques are often characterized by a thin fibrous cap, a large lipid core, and active inflammation. These features render plaques prone to rupture and thrombosis (blood clot formation).

In addition to improving clinical outcomes when used to guide PCI (percutaneous coronary intervention), intravascular imaging has also demonstrated something. Intravascular imaging has demonstrated that PCSK9 inhibitors, when added to high-intensity statin therapy, induce favorable changes in coronary plaque composition. These changes include thickening of the fibrous cap, reduction in lipid core, and decreased macrophage infiltration. These changes indicate plaque stabilization and reduced vulnerability.

These structural modifications, observable within just 12 months of therapy, underscore a mechanistic rationale for the early and clinically significant reduction in MACE observed in trials. Moreover, when considered in the context of the PROSPECT study, these findings acquire further clinical significance. Many recurrent events have been shown to arise from angiographically mild but high-risk nonculprit plaques, which may be particularly responsive to intensive LDL-C lowering therapy.

Clinical Implications: What This Means for Patients

In light of these mechanistic insights, the clinical implications of PCSK9 inhibitors are most compelling in patients with established ASCVD. In this population, vulnerable plaque morphology and residual inflammatory risk are prominent. However, real-world data consistently demonstrate underuse of PCSK9 inhibitors in eligible patients.

A key methodological strength of this network meta-analysis is the inclusion of patients with clinically manifest ASCVD, rather than a broader population that includes ASCVD risk equivalents. Patients with ASCVD risk equivalents often lack the advanced plaque phenotype seen in patients with prior myocardial infarction, stroke, or revascularization. Therefore, they may not have the same potential for short-term benefit from PCSK9 inhibition. By focusing on a pathophysiologically coherent, high-risk population, this study enhances both the internal validity and clinical relevance of its findings.

This design allows for a clearer delineation of the comparative effectiveness of different PCSK9-targeting agents in a setting where their mechanistic potential can be fully expressed. Furthermore, this design aligns closely with contemporary clinical practice guidelines. These guidelines emphasize the prioritization of PCSK9 inhibitors in patients with documented ASCVD and suboptimal LDL-C control despite maximally tolerated statin therapy.

Taken together, the findings highlight a series of observations:

• Several PCSK9 inhibitor regimens demonstrated statistically significant effects on individual MACE components. These include myocardial infarction reduction with evolocumab 420 mg QM/140 mg Q2W, stroke prevention with alirocumab 75 mg Q2W, and a broader endpoint improvement with alirocumab 150 mg Q2W.
• These results should be interpreted as exploratory signals rather than definitive evidence of superiority.
• The benefit observed with evolocumab 420 mg QM/140 mg Q2W on composite MACE is supported by a robust evidence base.

The apparent advantage of alirocumab 150 mg over inclisiran should be interpreted with caution. This result is based on limited data, specifically a single trial both for alirocumab 150 mg Q2W and for inclisiran. This raises the possibility that the observed difference may reflect trial-level variability rather than a true difference in clinical efficacy.

Notably, revascularization was the only secondary outcome showing significant differences in both direct and indirect comparisons. Alirocumab 150 mg Q2W emerged as the only regimen associated with a reduction in events compared with both evolocumab 420 mg QM/140 mg Q2W and alirocumab 75 mg Q2W. While these findings may suggest a greater impact of higher-intensity PCSK9 inhibition by alirocumab on ischemia-driven interventions, they remain exploratory and must be interpreted with caution.

The apparent differences between evolocumab and alirocumab may reflect differences in trial design and populations rather than intrinsic biological disparities between the two agents. For example, FOURIER enrolled patients with stable ASCVD, while ODYSSEY OUTCOMES included post-acute coronary syndrome patients with a slightly longer follow-up.

Moreover, evidence from FOURIER and its open-label extension (FOURIER-OLE) underscores that not only the magnitude but also the duration of LDL-C lowering is a key determinant of cardiovascular benefit. This supports the paradigm of "cholesterol-years exposure" as a driver of long-term outcomes and as an essential concept for interpreting the results of the present analysis. As such, these findings should be viewed as hypothesis-generating and warrant confirmation in adequately powered, direct head-to-head trials before guiding clinical decision-making.

Limitations: What the Study Could Not Prove

This analysis has several limitations that need to be mentioned.

1. Strict inclusion criteria limited the number of eligible trials. The network was constructed with strict inclusion criteria. While this ensured methodological rigor and enhanced the internal validity of comparisons, it also limited the number of eligible trials. This offered a more focused and clinically interpretable assessment of PCSK9 inhibitor efficacy in patients with established ASCVD.
2. MACE definitions varied across trials. The definitions of MACE varied slightly across the included trials. Several trials reported trial-specific composites, while others required reconstruction from individual components. This may have introduced a degree of variability.
3. Sample sizes and follow-up durations varied. Sample sizes were not uniformly large, and follow-up durations varied across studies. This reduces the generalizability of the results.
4. Limited evidence for some regimens. Evidence on inclisiran and alirocumab 150 mg Q2W was limited to a single trial. This may reduce the robustness of related estimates.
5. Safety outcomes were not fully assessed. The analysis focused on efficacy outcomes. Safety outcomes were not the primary focus of this study.

Recommendations and Takeaways

Based on this network meta-analysis, several key takeaways emerge for patients with established ASCVD:

1. PCSK9 inhibitors are effective in reducing major cardiovascular events. Evolocumab (140 mg every 2 weeks or 420 mg monthly) and alirocumab 150 mg every 2 weeks significantly reduced MACE compared with placebo in patients with established ASCVD.
2. Different regimens have different effects on specific outcomes. Evolocumab reduced heart attack, stroke, and revascularization. Alirocumab 75 mg reduced stroke. Alirocumab 150 mg reduced both stroke and revascularization.
3. No regimen significantly reduced death from any cause. None of the evaluated PCSK9 inhibitor regimens were associated with a significant reduction in cardiovascular death or all-cause mortality compared with placebo.
4. Deeper and more sustained LDL-C lowering may confer greater benefit. The findings reinforce the paradigm that "the lower, the better" for LDL cholesterol. Treatment strategies that achieve deeper and more sustained LDL-C lowering appear to yield greater clinical benefit.
5. Treatment selection should be individualized. In the absence of head-to-head trials, treatment selection is often guided by practical considerations. These include adherence, dosing frequency, and tolerability, rather than expectations of differential efficacy.
6. Discuss PCSK9 inhibitors with your healthcare provider. If you have established ASCVD and your LDL cholesterol remains above target despite maximally tolerated statin therapy, PCSK9 inhibitors may be an appropriate addition to your treatment plan. Clinical practice guidelines emphasize the prioritization of PCSK9 inhibitors in this setting.

The authors conclude that PCSK9 inhibitors are effective in ASCVD, with generally similar efficacy across agents. However, regimens achieving lower and sustained LDL-C levels may confer greater benefit. This is in line with the concept that "the lower, the better." These findings should be viewed as hypothesis-generating. These findings warrant confirmation in adequately powered, direct head-to-head trials before guiding clinical decision-making.

Frequently Asked Questions

I already take a high-intensity statin but still had a heart attack. Could a PCSK9 inhibitor help me?

In a network meta-analysis of 49,847 patients with established atherosclerotic cardiovascular disease, evolocumab (140 mg every 2 weeks or 420 mg monthly) and alirocumab 150 mg every 2 weeks significantly reduced major adverse cardiovascular events compared with placebo. No regimen significantly reduced cardiovascular or all-cause death. Discuss with your healthcare provider whether a PCSK9 inhibitor is appropriate for you.

What exactly is a PCSK9 inhibitor, and how does it lower cholesterol?

PCSK9 is a liver enzyme that promotes the breakdown of LDL cholesterol receptors on liver cells. PCSK9 inhibitors are monoclonal antibodies or small interfering RNA agents that block this interaction or silence PCSK9 messenger RNA. This increases the recycling of LDL receptors to the cell surface, enhancing clearance of LDL cholesterol from the bloodstream and producing profound, sustained reductions in LDL cholesterol levels.

Did any PCSK9 inhibitor regimen in this analysis reduce the risk of dying?

No. In this network meta-analysis of 49,847 patients with established atherosclerotic cardiovascular disease, none of the evaluated PCSK9 inhibitor regimens were associated with a significant reduction in cardiovascular death or all-cause mortality compared with placebo. The significant benefits were seen for major adverse cardiovascular events and some individual non-fatal outcomes, not for death.

What does a risk ratio of 0.78 for major cardiovascular events mean for me?

A risk ratio of 0.78 means patients taking that regimen had a 22% lower risk of major cardiovascular events compared with placebo. In this analysis, evolocumab 140 mg every 2 weeks or 420 mg monthly had a risk ratio of 0.78 (95% confidence interval 0.66–0.93) for major adverse cardiovascular events in patients with established atherosclerotic cardiovascular disease. Ask your clinician what this means for your situation.

Which PCSK9 inhibitor regimen reduced heart attack, stroke, or revascularization?

In this analysis, evolocumab 420 mg monthly or 140 mg every 2 weeks reduced heart attack (risk ratio 0.72), revascularization (0.77), and stroke (0.76) compared with placebo. Alirocumab 75 mg every 2 weeks reduced stroke (0.71). Alirocumab 150 mg every 2 weeks reduced stroke (0.13) and revascularization (0.39). These findings are exploratory and need confirmation in direct head-to-head trials.

Are these findings definitive, or do they need more research?

The authors describe these findings as hypothesis-generating. They warrant confirmation in adequately powered, direct head-to-head trials before guiding clinical decision-making. Evidence for inclisiran and alirocumab 150 mg every 2 weeks came from a single trial each, and the apparent advantage of alirocumab 150 mg over inclisiran should be interpreted with caution because it may reflect trial-level variability rather than a true difference.

Who was included in this analysis, and does it apply to me if I have not had a cardiovascular event?

The analysis included 49,847 adults with established atherosclerotic cardiovascular disease, such as prior heart attack, stroke, or revascularization, across eight randomized trials. Trials of primary prevention patients without evidence of atherosclerotic cardiovascular disease were excluded, as were people with risk equivalents such as familial hypercholesterolemia without prior events. If you have not had a cardiovascular event, these findings may not directly apply to you.

I have established atherosclerotic cardiovascular disease and my LDL cholesterol is still high on a statin — when should I seek a second opinion about adding a PCSK9 inhibitor?

A second opinion can be useful when your LDL cholesterol remains above target despite maximally tolerated statin therapy, since guidelines prioritize PCSK9 inhibitors in documented ASCVD. In a network meta-analysis of 49,847 patients, evolocumab and alirocumab 150 mg every 2 weeks significantly reduced major adverse cardiovascular events versus placebo, while no regimen significantly reduced cardiovascular or all-cause death. Because regimens differ in effects on heart attack, stroke, and revascularization, and treatment selection is individualized, an independent review can clarify which option fits your situation. Diagnostic Detectives Network provides independent expert second opinions.

Source Information

Original article title: Efficacy of PCSK9 Inhibitors on Clinical Outcomes in Patients with Established Atherosclerotic Cardiovascular Disease: A Network Meta-analysis.

Authors: Raone L, Gritti V, Mandurino-Mirizzi A, Sparasci FM, Scotti V, Currao A, Colonna G, Ferlini M, De Luca L.

Publication: American Journal of Cardiovascular Drugs (2026) 26:193–203

DOI: https://doi.org/10.1007/s40256-025-00778-1

Publication date: Published online 20 December 2025

Trial registration: PROSPERO identifier no. CRD420251022108

Author affiliations: Department of Molecular Medicine, University of Pavia, Pavia, Italy; Division of Cardiology, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy; Division of Cardiology, Vito Fazzi Hospital, Lecce, Italy; Department of Experimental Medicine (DiMeS), University of Salento, Lecce, Italy; Centre for Scientific Documentation, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy; Department of Internal Medicine and Medical Therapy, University of Pavia, Pavia, Italy

This patient-friendly article is based on peer-reviewed research.